Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24896382 | 0.88 | GRM4 (0.35) | GRM4ANO1CNR2IRAK4HPGDS | |
| SCHEMBL24896261 | 0.85 | GRM4 (0.39) | GRM4ANO1CNR2TP53CNR1 | |
| SCHEMBL24896350 | 0.84 | GRM4 (0.41) | GRM4ANO1CNR2PHGDHCNR1 | |
| SCHEMBL24896274 | 0.84 | GRM4 (0.37) | GRM4ANO1CNR2IRAK4 | |
| SCHEMBL24896379 | 0.83 | GRM4 (0.38) | GRM4ANO1CFTRCNR2CNR1 | |
| SCHEMBL24896300 | 0.83 | GRM4 (0.38) | GRM4ANO1CNR2HPGDSCNR1 | |
| SCHEMBL24896273 | 0.83 | GRM4 (0.38) | GRM4ANO1CNR2CNR1 | |
| SCHEMBL24896384 | 0.82 | GRM4 (0.37) | GRM4ANO1CNR2HPGDSCNR1 | |
| SCHEMBL24896277 | 0.77 | ANO1 (0.40) | GRM4ANO1CFTRCNR2PHGDH | |
| SCHEMBL30220608 | 0.77 | L3MBTL1 (0.50) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GRM4 461/4885ANO1 2433/4885CFTR 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.